Eli Lilly enters $35m immunology R&D deal

25-04-2019

Eli Lilly enters $35m immunology R&D deal

Jonathan Weiss / Shutterstock.com

Eli Lilly has entered into a $35m global licensing and research agreement with biotech company Avidity Biosciences.


Eli Lilly, Avidity Biosciences, licensing and research agreement, immunology, oligonucleotides, antibodies, DNA

LSIPR